NCT05223920

An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients With Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat Clinical Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 81 (actual)
• Sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in participants with a Myeloproliferative Neoplasm (MPN) who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003 (NCT04254978) (referred to hereafter as 'feeder studies').

Conditions

• Thrombocythemia, Essential
• Primary Myelofibrosis

Interventions

Type	Name	Description
DRUG	Bomedemstat	Capsule (oral)

Timeline

• Start date: 2021-12-15
• Primary completion: 2024-08-22
• Completion: 2024-08-22
• First posted: 2022-02-04
• Last updated: 2025-09-22
• Results posted: 2025-09-22

Locations

19 sites across 7 countries: United States, Australia, Germany, Hong Kong, Italy, New Zealand, United Kingdom

Regulatory

• FDA-regulated drug study